Clinical trial
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion…
NCT05241873 · Blueprint Medicines Corporation, Industry · Terminated
Key facts
| NCT number | NCT05241873 |
|---|---|
| Title | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations |
| Official title | Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations |
| Lead sponsor | Blueprint Medicines Corporation, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Disease, Bronchogenic, Bronchial Neoplasms and 11 more |
| Intervention type | Drug |
| Interventions | BLU-451, Carboplatin, Pemetrexed |
| Enrollment | 103 |
| Start date | Mar 4, 2022 |
| Primary completion | Jul 31, 2024 |
| Completion | Jul 31, 2024 |
| First posted | Feb 16, 2022 |
| Last update posted | Feb 10, 2025 |
| Countries | Canada, Japan, South Korea, Taiwan, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: